Price Action Report: What’s Moleculin Biotech Inc Upside After Today’s Huge Increase?

Price Action Report: What's Moleculin Biotech Inc Upside After Today's Huge Increase?

The stock of Moleculin Biotech Inc (NASDAQ:MBRX) is a huge mover today! About 119,464 shares traded hands. Moleculin Biotech Inc (NASDAQ:MBRX) has risen 6.00% since October 1, 2016 and is uptrending. It has outperformed by 2.53% the S&P500.
The move comes after 8 months positive chart setup for the $34.71 million company. It was reported on Oct, 31 by We have $7.09 PT which if reached, will make NASDAQ:MBRX worth $37.49 million more.

Analysts await Moleculin Biotech Inc (NASDAQ:MBRX) to report earnings on November, 21.

According to Zacks Investment Research, “Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.”

More notable recent Moleculin Biotech Inc (NASDAQ:MBRX) news were published by: which released: “News Moleculin Biotech Inc.MBRX” on February 11, 2011, also with their article: “Moleculin Biotech, Inc. Completes Initial Public Offering; MBRX Shares Set to …” published on June 01, 2016, published: “Moleculin Biotech, Inc. Announces Acquisition of Annamycin Rights” on October 28, 2015. More interesting news about Moleculin Biotech Inc (NASDAQ:MBRX) were released by: and their article: “Moleculin Biotech (MBRX) Advances WP1122 into Preclinical Stage” published on October 26, 2016 as well as‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: June 02, 2016.

MBRX Company Profile

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Firm is focused on the development of anti-cancer drug candidates, many of which are based on license agreements. The Company’s lead drug candidate is liposomal Annamycin (Annamycin). The Firm has two other drug development projects in progress, one involving a portfolio of small molecules, known as the WP1066 Portfolio, and the other is WP1122 Portfolio. WP1066 Portfolio is focused on the modulation of key regulatory transcription factors involved in the progression of cancer. WP1122 Portfolio is a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (a form of brain tumor).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment